We recently compiled a list of the Jim Cramer Shed Light on These 8 Stocks Recently. In this article, we are going to take a ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...

AbbVie Inc . (NYSE:ABBV), a Delaware-incorporated pharmaceutical company with a market capitalization of $339 billion and annual revenue exceeding $56 billion, has entered into a $3 billion unsecured ...

AbbVie (NYSE:ABBV – Get Free Report) had its price target lifted by equities researchers at UBS Group from $181.00 to $190.00 in a note issued to investors on Monday,Benzinga reports. The brokerage ...

AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter ...

AbbVie (NYSE:ABBV – Get Free Report) had its target price raised by equities research analysts at Wells Fargo & Company from $195.00 to $210.00 in a note issued to investors on Monday,Benzinga reports ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

AbbVie Inc. closed 15.68% short of its 52-week high of $207.32, which the company achieved on October 31st.

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $183.9 which represents a slight increase of $8.25 or 4.70% from the prior close of $175.65. The stock opened at $187.3 and touched a low ...

AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...